Cargando…

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kun-Peng, Jin, Jing-Yu, Yang, Jin-Shui, Li, Yan, Zhao, Wei, Luo, Gui, Zhu, Jian, Zhang, Jiang-Lin, Huang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524190/ https://www.ncbi.nlm.nih.gov/pubmed/31110537 http://dx.doi.org/10.5114/aoms.2018.76141

Ejemplares similares

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
por: Van Rossen, Liz, et al.
Publicado: (2020)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
por: Chen, Yilin, et al.
Publicado: (2023)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
por: Gratacós, Jordi, et al.
Publicado: (2019)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis
por: Zong, He-xiang, et al.
Publicado: (2022)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
por: Maksymowych, Walter P, et al.
Publicado: (2016)

Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability
por: Bandinelli, Francesca, et al.
Publicado: (2016)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Adequately dosed aerobic physical activity in people with axial spondyloarthritis: associations with physical therapy
por: Hilberdink, Bas, et al.
Publicado: (2020)

Future of Low-Dose Computed Tomography and Dual-Energy Computed Tomography in Axial Spondyloarthritis
por: Diekhoff, Torsten, et al.
Publicado: (2022)

Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Patients with Axial Spondyloarthritis Are at Risk of Developing Adhesive Capsulitis: Real-World Evidence Database Study in Taiwan
por: Huang, Shih-Wei, et al.
Publicado: (2020)

Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Genetics and the axial spondyloarthritis spectrum
por: Brown, Matthew A, et al.
Publicado: (2020)

Correction: Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Publicado: (2020)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Acute Q Fever in an Ankylosing Spondyloarthritis Patient Treated with Etanercept
por: Guiga, A., et al.
Publicado: (2021)

Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study
por: Luciano, Nicoletta, et al.
Publicado: (2022)

Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis, Elizabeth Mary, et al.
Publicado: (2014)

Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy
por: Li, Yebei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sh7mt5b52hg7vgdvnr7lfp9jh3